Icotrokinra demonstrated superiority to placebo and deucravacitinib in the treatment of adults and adolescents with moderate ...

First results from the BeNeBio study show that doses of IL-17 and IL-23 inhibitors can be reduced by up to 50% in people with ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque ...

A recent review explored the benefits of biosimilars for patients with moderate to severe chronic plaque psoriasis.

The FDA has expanded the approval of Tremfya to include pediatric patients 6 years and older weighing at least 40kg for the treatment of moderate to severe plaque PsO and active PsA.

Early apremilast initiation is associated with reduced psoriasis activity and burden compared with late initiation or continued topical therapy use.

Sustained two-year treatment with tildrakizumab improved the psychological well-being of people with moderate to severe ...

Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, announces ...

Bristol Myers Squibb Co said on Tuesday its experimental plaque psoriasis oral drug proved more effective in clearing moderate to severe cases of the skin condition than placebo or Amgen Inc's Otezla ...

Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented data package includes head-to-head superiority comparisons versus deucravacitinib, adolescent ...